Entera Bio (NASDAQ:ENTX) Trading Up 7.1% – What’s Next?

Entera Bio Ltd. (NASDAQ:ENTX) shares shot up 7.1% during mid-day trading on Monday . The stock traded as high as $1.96 and last traded at $1.95. 62,842 shares traded hands during mid-day trading, a decline of 25% from the average session volume of 83,521 shares. The stock had previously closed at $1.82.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright upgraded Entera Bio to a “strong-buy” rating in a research note on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, According to MarketBeat, the stock has an average rating of “Strong Buy” and a consensus price target of $10.00.

Entera Bio Trading Up 7.1%

The company has a market capitalization of $89.04 million, a P/E ratio of -7.50 and a beta of 1.69. The company’s fifty day moving average is $1.92 and its 200 day moving average is $1.93.

Entera Bio (NASDAQ:ENTX) last issued its earnings results on Friday, August 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.05. Entera Bio had a negative net margin of 4,525.11% and a negative return on equity of 77.75%. Equities research analysts predict that Entera Bio Ltd. will post -0.28 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ENTX. HighTower Advisors LLC grew its holdings in Entera Bio by 53.3% during the 1st quarter. HighTower Advisors LLC now owns 18,140 shares of the company’s stock valued at $31,000 after buying an additional 6,310 shares in the last quarter. Parkman Healthcare Partners LLC boosted its position in shares of Entera Bio by 6.3% in the first quarter. Parkman Healthcare Partners LLC now owns 439,632 shares of the company’s stock valued at $747,000 after acquiring an additional 25,900 shares during the period. Finally, Bessemer Group Inc. bought a new position in shares of Entera Bio in the second quarter valued at approximately $268,000. Institutional investors own 14.11% of the company’s stock.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.